Neratinib causes significant gastrointestinal toxicity, particularly diarrhoea which can be severe, leads to a high rate of discontinuation, and may affect quality of life. The extent to which these effects may be ameliorated by anti-diarrhoeal prophylaxis is unclear at this time. In the absence of established efficacy, the toxicity cannot be considered acceptable.